News | May 10, 2024
Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company is committed to address this observation comprehensively within stipulated time
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
The product is used to treat amyotrophic lateral sclerosis
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
